Skip to main content
Top
Published in: Clinical Rheumatology 3/2017

Open Access 01-03-2017 | Original Article

Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart

Authors: Magnus Husberg, Thomas Davidson, Eva Hallert

Published in: Clinical Rheumatology | Issue 3/2017

Login to get access

Abstract

The aim of the present study was to calculate non-medical costs during year 1 after diagnosis in two cohorts of patients with early rheumatoid arthritis enrolled 1996–1998 and 2006–2009. Clinical data were collected regularly in both cohorts. Besides information about healthcare utilization and days lost from work, patients reported non-medical costs for aids/devices, transportation, formal and informal care. Formal care was valued as full labour cost for official home help (€42.80/h) and informal care from relatives and friends as opportunity cost of leisure time, corresponding to 35% of labour cost (€15/h). In both cohorts, only 2% used formal care, while more than 50% used informal care. Prescription of aids/devices was more frequent in cohort 2 and more women than men needed aids/devices. Help with transportation was also more common in cohort 2. Women in both cohorts needed more informal care than men, especially with personal care and household issues. Adjusting for covariates in regression models, female sex remained associated with higher costs in both cohorts. Non-medical costs in cohort 2 were €1892, €1575 constituting informal care, corresponding to 83% of non-medical costs. Total non-medical costs constituted 25% of total direct costs and 11% of total direct and indirect costs. Informal care accounted for the largest part of non-medical costs and women had higher costs than men. Despite established social welfare system, it is obvious that family and friends, to a large extent, are involved in informal care of patients with early RA, and this may underestimate the total burden of the disease.
Literature
1.
go back to reference Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P (2014) Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in Sweden. Rheumatology 53:153–160CrossRefPubMed Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P (2014) Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in Sweden. Rheumatology 53:153–160CrossRefPubMed
2.
go back to reference Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, Cortesi PA, Turchetti G (2012) Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 30(Suppl 73):S72–S84PubMed Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, Cortesi PA, Turchetti G (2012) Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 30(Suppl 73):S72–S84PubMed
3.
go back to reference Hallert E, Husberg M, Jonsson D, Skogh T (2004) Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology 43:1374–1382CrossRefPubMed Hallert E, Husberg M, Jonsson D, Skogh T (2004) Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology 43:1374–1382CrossRefPubMed
4.
go back to reference Lenssinck ML, Burdorf A, Boonen A, Gignac MA, Hazes JM, Luime JJ (2013) Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review. Ann Rheum Dis 72:493–505CrossRefPubMed Lenssinck ML, Burdorf A, Boonen A, Gignac MA, Hazes JM, Luime JJ (2013) Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review. Ann Rheum Dis 72:493–505CrossRefPubMed
5.
go back to reference Eriksson JK, Johansson K, Askling J, Neovius M (2015) Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? Ann Rheum Dis 74:648–654CrossRefPubMed Eriksson JK, Johansson K, Askling J, Neovius M (2015) Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed? Ann Rheum Dis 74:648–654CrossRefPubMed
6.
go back to reference Hallert E, Husberg M, Bernfort L (2012) The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990–2010: before and after introduction of biologic agents. Rheumatology 51:338–346CrossRefPubMed Hallert E, Husberg M, Bernfort L (2012) The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990–2010: before and after introduction of biologic agents. Rheumatology 51:338–346CrossRefPubMed
7.
go back to reference Uhlig T, Heiberg PM, Kvien TK (2008) Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994–2004. Ann Rheum Dis 67:1710–1715CrossRefPubMed Uhlig T, Heiberg PM, Kvien TK (2008) Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994–2004. Ann Rheum Dis 67:1710–1715CrossRefPubMed
8.
go back to reference Uhlig T, Moe RH, Kvien TK (2014 Sep) The burden of disease in rheumatoid arthritis. PharmacoEconomics 32:841–851CrossRefPubMed Uhlig T, Moe RH, Kvien TK (2014 Sep) The burden of disease in rheumatoid arthritis. PharmacoEconomics 32:841–851CrossRefPubMed
9.
go back to reference Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62:1576–1582CrossRefPubMedPubMedCentral Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62:1576–1582CrossRefPubMedPubMedCentral
10.
go back to reference Hallert E, Husberg M, Kalkan A, Bernfort L (2016) Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09. Scand J Rheumatol 45:371–378CrossRefPubMed Hallert E, Husberg M, Kalkan A, Bernfort L (2016) Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09. Scand J Rheumatol 45:371–378CrossRefPubMed
11.
go back to reference Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford University Press, Oxford; New York Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford University Press, Oxford; New York
12.
go back to reference Hülsemann JL, Mittendorf T, Merkesdal S, Handelmann S, von der Schulenburg JM, Zeidler H, Ruof J (2005) Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis 64:1456–1461CrossRefPubMedPubMedCentral Hülsemann JL, Mittendorf T, Merkesdal S, Handelmann S, von der Schulenburg JM, Zeidler H, Ruof J (2005) Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis 64:1456–1461CrossRefPubMedPubMedCentral
13.
go back to reference Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J (2008) Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 75:408–415CrossRefPubMed Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J (2008) Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 75:408–415CrossRefPubMed
14.
go back to reference EUnetHTA Joint Action 2, Work Package 7, Subgroup 3, Heintz E, Gerber-Grote A, Ghabri S, Hamers F, Prevolnik Rupel V, Slabe-Erker R, Davidson T (2016) Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. PharmacoEconomics 34:59–76CrossRef EUnetHTA Joint Action 2, Work Package 7, Subgroup 3, Heintz E, Gerber-Grote A, Ghabri S, Hamers F, Prevolnik Rupel V, Slabe-Erker R, Davidson T (2016) Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. PharmacoEconomics 34:59–76CrossRef
15.
go back to reference Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LBA, van Riel (1995) Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 38:44–48CrossRefPubMed Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LBA, van Riel (1995) Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 38:44–48CrossRefPubMed
16.
go back to reference Ekdahl C, Eberhardt KB, Andersson SI, Svensson B (1988) Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 17:263–271CrossRefPubMed Ekdahl C, Eberhardt KB, Andersson SI, Svensson B (1988) Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 17:263–271CrossRefPubMed
17.
go back to reference EuroQol G (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef EuroQol G (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
18.
19.
go back to reference Westhovens R, Boonen A, Verbruggen L, Durez P, De Clerck L, Malaise M, Mielants H (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24:615–619CrossRefPubMed Westhovens R, Boonen A, Verbruggen L, Durez P, De Clerck L, Malaise M, Mielants H (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24:615–619CrossRefPubMed
20.
go back to reference Turchetti G, Bellelli S, Mosca M (2014) The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise. Reumatismo 65:271–277CrossRefPubMed Turchetti G, Bellelli S, Mosca M (2014) The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise. Reumatismo 65:271–277CrossRefPubMed
21.
go back to reference Lundkvist J, Kastang F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8(Suppl 2):S49–S60CrossRefPubMed Lundkvist J, Kastang F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8(Suppl 2):S49–S60CrossRefPubMed
22.
go back to reference Van den Berg B, Spauwen P (2006) Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving. Health Econ 15:447–460CrossRefPubMed Van den Berg B, Spauwen P (2006) Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving. Health Econ 15:447–460CrossRefPubMed
23.
go back to reference Davidson T, Levin LA (2010) Is the societal approach wide enough to include relatives? Incorporating relatives’ costs and effects in a cost-effectiveness analysis. Appl Health Econ Health Policy 8:25–35CrossRefPubMed Davidson T, Levin LA (2010) Is the societal approach wide enough to include relatives? Incorporating relatives’ costs and effects in a cost-effectiveness analysis. Appl Health Econ Health Policy 8:25–35CrossRefPubMed
24.
go back to reference Van den Berg B, Gafni A, Portrait F (2013) Attributing a monetary value to patients’ time: a contingent valuation approach. In: CHE research paper 90. Centre for Health Economics. The university of York, York Van den Berg B, Gafni A, Portrait F (2013) Attributing a monetary value to patients’ time: a contingent valuation approach. In: CHE research paper 90. Centre for Health Economics. The university of York, York
25.
go back to reference Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM (2008) Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient’s perspective. Rheumatology 47:188–193CrossRefPubMed Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM (2008) Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient’s perspective. Rheumatology 47:188–193CrossRefPubMed
26.
go back to reference Fautrel B, Cukierman G, Joubert JM, Laurendeau C, Gourmelen J, Fagnani F (2016) Healthcare service utilisation costs attributable to rheumatoid arthritis in France: analysis of a representative national claims database. Joint Bone Spine 83:53–56CrossRefPubMed Fautrel B, Cukierman G, Joubert JM, Laurendeau C, Gourmelen J, Fagnani F (2016) Healthcare service utilisation costs attributable to rheumatoid arthritis in France: analysis of a representative national claims database. Joint Bone Spine 83:53–56CrossRefPubMed
27.
go back to reference Verstappen SM (2015) Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol 29:495–511CrossRefPubMed Verstappen SM (2015) Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol 29:495–511CrossRefPubMed
Metadata
Title
Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart
Authors
Magnus Husberg
Thomas Davidson
Eva Hallert
Publication date
01-03-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3470-z

Other articles of this Issue 3/2017

Clinical Rheumatology 3/2017 Go to the issue